Literature DB >> 11026485

NMDA channel blockers: memantine and amino-aklylcyclohexanes--in vivo characterization.

W Danysz1, C G Parsons, G Quack.   

Abstract

The previous overviews provided the basis for better therapeutic efficacy/tolerability of low to moderate affinity NMDA channel blockers. This prediction finds support in in vitro studies comparing protective and plasticity impairing effects (therapeutic vs. side-effect) of memantine and (+)MK-801. In fact it turned out that memantine had a far better therapeutic index. But can it be confirmed in the in vivo situation?

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11026485

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  5 in total

1.  Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses.

Authors:  Peng Xia; Huei-sheng Vincent Chen; Dongxian Zhang; Stuart A Lipton
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

Review 2.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

3.  Memantine fails to facilitate partial cigarette deprivation in smokers--no role of Memantine in the treatment of nicotine dependency?

Authors:  N Thuerauf; J Lunkenheimer; B Lunkenheimer; W Sperling; S Bleich; M Schlabeck; J Wiltfang; J Kornhuber
Journal:  J Neural Transm (Vienna)       Date:  2006-10-18       Impact factor: 3.575

Review 4.  Non-cholinergic strategies for treating and preventing Alzheimer's disease.

Authors:  P Murali Doraiswamy
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones.

Authors:  A R Wild; E Akyol; S L C Brothwell; P Kimkool; J N Skepper; A J Gibb; S Jones
Journal:  Neuropharmacology       Date:  2013-05-28       Impact factor: 5.250

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.